25.53
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$25.87
Offen:
$25.83
24-Stunden-Volumen:
35.74M
Relative Volume:
0.87
Marktkapitalisierung:
$144.68B
Einnahmen:
$63.63B
Nettoeinkommen (Verlust:
$8.03B
KGV:
18.11
EPS:
1.41
Netto-Cashflow:
$8.23B
1W Leistung:
-1.31%
1M Leistung:
-4.45%
6M Leistung:
-10.58%
1J Leistung:
-7.37%
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PFE
Pfizer Inc
|
25.53 | 144.68B | 63.63B | 8.03B | 8.23B | 1.41 |
![]()
LLY
Lilly Eli Co
|
865.00 | 822.10B | 45.04B | 10.59B | -2.28B | 11.71 |
![]()
NVO
Novo Nordisk Adr
|
83.74 | 371.73B | 42.09B | 14.65B | 10.11B | 3.2833 |
![]()
JNJ
Johnson Johnson
|
156.13 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
![]()
ABBV
Abbvie Inc
|
191.83 | 338.99B | 56.33B | 4.28B | 15.62B | 2.40 |
![]()
MRK
Merck Co Inc
|
86.54 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
2024-10-25 | Fortgesetzt | Citigroup | Neutral |
2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
2024-03-22 | Herabstufung | Argus | Buy → Hold |
2024-02-23 | Eingeleitet | Guggenheim | Buy |
2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
2023-10-20 | Fortgesetzt | UBS | Neutral |
2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
2023-07-17 | Bestätigt | JP Morgan | Neutral |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
2023-03-06 | Eingeleitet | Jefferies | Hold |
2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
2023-01-26 | Herabstufung | UBS | Buy → Neutral |
2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
2021-12-20 | Bestätigt | Cowen | Outperform |
2021-12-17 | Eingeleitet | Goldman | Neutral |
2021-12-13 | Hochstufung | UBS | Neutral → Buy |
2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
2021-07-27 | Fortgesetzt | Truist | Buy |
2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2020-11-19 | Fortgesetzt | Goldman | Neutral |
2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
2020-09-29 | Eingeleitet | Berenberg | Hold |
2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
2020-02-27 | Eingeleitet | Barclays | Equal Weight |
2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
2020-02-06 | Eingeleitet | Mizuho | Buy |
2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
2019-02-20 | Fortgesetzt | Citigroup | Neutral |
2019-01-31 | Hochstufung | Argus | Hold → Buy |
2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
2019-01-23 | Herabstufung | UBS | Buy → Neutral |
2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Kentucky Trust Co Buys New Stake in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Sold by Capital Advisors Inc. OK - MarketBeat
Certuity LLC Grows Stock Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Community Financial Services Group LLC Sells 11,699 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Louisiana State Employees Retirement System Cuts Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Sold by Beacon Financial Group - MarketBeat
Harbor Advisory Corp MA Sells 24,417 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
17,720 Shares in Pfizer Inc. (NYSE:PFE) Bought by Augustine Asset Management Inc. - MarketBeat
Pfizer: 3 Key Risks That Warrant A Sell (NYSE:PFE) - Seeking Alpha
Pediatric Vaccine Market Research Report 2025: Merck & Co. - GlobeNewswire
Sovran Advisors LLC Takes Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Uncover the Next Big Investment Opportunity: Why Pfizer Is a Top Pick - Jomfruland.net
Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform - BioSpace
Pfizer, Alloy Therapeutics unite on new antibody discovery platform - Medical Dialogues
Brokers Issue Forecasts for Pfizer's Q3 Earnings (NYSE:PFE) - MarketBeat
Pfizer Seeks FDA Clearance For COVID-19 Vaccine In Younger Children - BW Healthcare World
Alloy Partners with Pfizer to Develop New Antibody Discovery Platform - Contract Pharma
Pfizer's Options Frenzy: What You Need to Know - Benzinga
Pfizer (NYSE:PFE) Stock Price Down 1.1%Here's What Happened - MarketBeat
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo - Benzinga
Alloy and Pfizer in latest strategic collaboration - The Pharma Letter
Pfizer's investigational candidate combo cuts prostate cancer progression by 49% in phase 1 - Fierce Biotech
Pfizer: strategic collaboration with Alloy extended -February 11, 2025 at 10:56 am EST - Marketscreener.com
Jefferies raises Pfizer stock price target to $34, maintains Buy - Investing.com
Leaked Conference Article Shows Pfizer’s Positive Phase I Prostate Cancer Data - BioSpace
Jefferies Adjusts Price Target on Pfizer to $34 From $33 -February 11, 2025 at 09:55 am EST - Marketscreener.com
Why Pfizer Stock Popped Today - AOL
Pfizer reports positive long-term results for Padcev, Keytruda combo in urothelial cancer - World Pharmaceutical Frontiers
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Nasdaq
Active Pharmaceutical Ingredients (API) Market Growth, Trends, Demand & Outlook 2025-2032 | Teva - EIN News
Pfizer Inc. (NYSE:PFE) Shares Sold by First Fiduciary Investment Counsel Inc. - MarketBeat
Pfizer Inc. (NYSE:PFE) Position Increased by Essex Financial Services Inc. - MarketBeat
Sapient Capital LLC Has $13.79 Million Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Sold by Savant Capital LLC - MarketBeat
Chronic Pain Market Detailed In New Research Report 2025 | Pfizer - openPR
Strategic Financial Concepts LLC Buys Shares of 85,974 Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer To Sell All Its Drugs At Non-profit Price In Low-income Countries - BW Healthcare World
Sangamo Therapeutics: Challenging Road Ahead After Pfizer Exit (NASDAQ:SGMO) - Seeking Alpha
Leo Wealth LLC Has $949,000 Stock Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Sold by Slocum Gordon & Co LLP - MarketBeat
Cantor Fitzgerald Investment Advisors L.P. Trims Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Wilmington Savings Fund Society FSB Has $8.27 Million Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Archer Investment Corp Sells 33,232 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Golden State Wealth Management LLC Makes New Investment in Pfizer Inc. (NYSE:PFE) - MarketBeat
BLB&B Advisors LLC Lowers Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Sold by Bleakley Financial Group LLC - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Purchased by Quattro Financial Advisors LLC - MarketBeat
Pfizer (NYSE:PFE) Shares Down 0.8%Time to Sell? - MarketBeat
Pfizer and Astellas report improved survival in bladder cancer trial - Investing.com India
Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer - Marketscreener.com
Pfizer And Astellas' Padcev Plus Keytruda Shows Long-Term Efficacy In First-Line Treatment Of Locally Advanced Or Metastatic Urothelial Cancer - Marketscreener.com
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):